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Strong evidence indicates that regulated mRNA
translation in neuronal dendrites underlies synaptic
plasticity and brain development. The fragile X men-
tal retardation protein (FMRP) is involved in this
process; here, we show that it acts by inhibiting
translation initiation. A binding partner of FMRP,
CYFIP1/Sra1, directly binds the translation initiation
factor eIF4E through a domain that is structurally re-
lated to those present in 4E-BP translational inhibi-
tors. Brain cytoplasmic RNA 1 (BC1), another FMRP
binding partner, increases the affinity of FMRP for
the CYFIP1-eIF4E complex in the brain. Levels of
proteins encoded by known FMRP target mRNAs
are increased upon reduction of CYFIP1 in neurons.
Translational repression is regulated in an activity-
dependent manner because BDNF or DHPG stimula-
tion of neurons causes CYFIP1 to dissociate from
eIF4Eatsynapses, thereby resulting inprotein synthe-
sis. Thus, the translational repressionactivity ofFMRP
in the brain is mediated, at least in part, by CYFIP1.
INTRODUCTION
The construction of neuronal circuits in the developing brain re-
quires the correct assembly of trillions of synaptic connections.
Finely regulated protein synthesis may be required to obtain
the correct set of proteins at synapses and to modulate their ac-
tivity in response to different developmental cues or synaptic
stimulations. Indeed, accumulating evidence indicates that local
(synaptodendritic) protein synthesis modulates synaptic plastic-
ity (Martin et al., 2000; Steward and Schuman, 2003; Pfeiffer and
Huber, 2006; Lin and Holt, 2008). Although the general transla-
tional machinery has been found at or near synapses, compo-1042 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.nents that might control specific mRNA translation in that com-
partment are largely unknown.
One protein implicated in neuronal mRNA translation is the
fragile X mental retardation protein (FMRP), the absence of
which causes the fragile X syndrome (FXS) that is characterized
at the cellular level by a deficit in synapse maturation. FMRP is an
RNA-binding protein with roles in mRNA localization, translation
(Bagni and Greenough, 2005), and stability (Zalfa et al., 2007;
Zhang et al., 2007). It recognizes mRNAs by directly interacting
with them through G quartets and/or U-rich sequences or
through small, noncoding RNA adaptors such as the brain
cytoplasmic RNA BC1 and possibly microRNAs (Bagni and
Greenough, 2005). Strong evidence indicates that FMRP re-
presses translation, although how it does so is enigmatic.
Two well-characterized pathways that affect local protein
synthesis in neurons involve activation of the TrkB receptors
(Steward and Schuman, 2003; Schratt et al., 2004) by the neuro-
trophin BDNF and stimulation of the group 1 metabotropic gluta-
mate receptors (mGluRs) (Weiler and Greenough, 1993). BDNF
treatment activates the translation of two dendritic FMRP target
mRNAs that encode Arc/Arg3.1 and aCaMKII (Aakalu et al.,
2001; Yin et al., 2002; Zalfa et al., 2003; Schratt et al., 2004).
On the other hand, FMRP is also regulated in response to mGluR
stimulation (Weiler et al., 1997; Antar et al., 2004; Ferrari et al.,
2007); moreover, long-term depression (LTD), triggered by acti-
vation the of mGluRs, is enhanced in the hippocampus of mutant
mice lacking FMRP (Huber et al., 2002).
One possible mechanism for regulating translation is by mod-
ulation of the interactions between factors required for transla-
tional initiation. Cap-dependent translation, which requires the
association of the eIF4A-eIF4G-eIF4E (eIF4F) complex with the
50 terminal m7G cap, is known to be particularly important in neu-
rons (Richter and Sonenberg, 2005). eIF4F assembly is often
regulated by the 4E binding proteins (4E-BPs), which interfere
with the eIF4E-eIFG interaction (Richter and Sonenberg, 2005;
Richter and Klann, 2007; Banko et al., 2007). eIF4E-binding pro-
teins, including 4E-T and eIF4G, share a motif that is responsible
for their association with eIF4E. Although 4E-BP1, BP2, BP3,
and 4E-T, which all block the eIF4G-eIF4E interaction, probably
act as general regulators, other proteins such as Xenopus Mas-
kin and Drosophila Cup act as mRNA-specific 4E-BPs (Richter
and Sonenberg, 2005). Thus far, only Neuroguidin has been
identified as a 4E-BP in the nervous system (Jung et al., 2006).
Here, we demonstrate that FMRP-mediated repression of
translation requires an interaction with Cytoplasmic FMRP Inter-
acting Protein CYFIP1 (Schenck et al., 2001; Schenck et al.,
2003) also known as Sra-1 (Kobayashi et al., 1998), which also
binds the cap-binding factor eIF4E. The eIF4E-interacting do-
main of CYFIP1 forms the characteristic ‘‘reverse L shaped’’
structure that is also assumed by the canonical eIF4E-binding
motif (Marcotrigiano et al., 1999). Modulation of CYFIP1 levels
affects general mRNA translation in mammalian cells. In the
brain, however, CYFIP1 forms a complex with specific FMRP-tar-
get mRNAs; reduced levels of CYFIP1 cause an increase in the
synthesis of MAP1B, aCaMKII, and APP, whose mRNAs are
known to be regulated by FMRP (Bagni and Greenough, 2005;
Hou et al., 2006; Westmark and Malter, 2007). Our data indicate
that an eIF4E-CYFIP1-FMRP complex is present at synapses
and that synaptic activity releases CYFIP1 from eIF4E, as well
as from bound RNAs, resulting in the alleviation of translation
repression.
RESULTS
FMRP Cosediments with Light mRNPs in a Complex
Possibly Containing Both eIF4E and CYFIP1
To investigate the mechanism by which FMRP represses trans-
lation in neurons, we examined the distribution of FMRP in su-
crose gradients. As shown in Figure 1A, FMRP cofractionated
with mRNPs with sedimentation values ranging from 40S to
80S. This profile is similar to the one observed for translational
regulators such as mammalian p27/eIF6 and eIF4E (Figure 1A
and Figure S1 available online). Interestingly, CYFIP1, which in-
teracts with FMRP in the cytoplasm (Schenck et al., 2001), par-
tially cofractionated with FMRP and eIF4E (Figure 1A, lanes 6–9,
and Figure S1). Poly(A)-binding protein (PABP), which associates
with translationally active and inactive mRNAs, cosedimented
with mRNPs (Figure 1A), as well as with heavy polysomes
(Figure S1). These sedimentation experiments suggest that
FMRP, CYFIP, and eIF4E might reside in a common complex,
perhaps with mRNA.
The FMRP-CYFIP1 Complex Binds eIF4E
and PABP in Brain
We next investigated whether the FMRP-CYFIP1 complex could
be retained with eIF4E on m7GTP-Sepharose. When the beads
were incubated with total brain cytoplasmic extracts, both
FMRP and CYFIP1 were recovered from them but only after spe-
cific elution with m7GTP (Figure 1B, lane 3). Whereas the recov-
ery of FMRP varied according to salt concentration (data not
shown), CYFIP1 recovery was not particularly salt sensitive.
PABP was also present in the m7GTP eluate, whereas two other
proteins not involved in mRNA translation, b-tubulin and reticu-
lon 1C, were not specifically eluted. Interestingly, WAVE, a cyto-
plasmic protein interacting with CYFIP1 (Bogdan et al., 2004),Cwas also mostly not retained on the beads (Figure 1B, lane 3),
suggesting a specific function of the FMRP-CYFIP1-eIF4E
complex. Furthermore, neither CYFIP1 nor FMRP (Figure 1B,
compare lanes 5 and 6) was present in the last wash; GTP greatly
reduced the yield of the eluted complex (Figure 1B, lane 7), dem-
onstrating the efficiency and specificity of the m7GTP elution.
The FMRP-CYFIP1-eIF4E complex was also coprecipitated
from brain extracts with specific FMRP antibody (Ferrari et al.,
2007). A specific interaction among FMRP, eIF4E, and CYFIP1
was detected in wild-type (Figure 1C, lane 4) but not in FMR1
knockout (KO) mice (Figure 1C, lane 3) (Bakker et al., 1994).
RNase A treatment did not destroy the CYFIP1-FMRP-eIF4E in-
teraction as assessed by CYFIP1 antibody coprecipitation
(Figure 1D, compare lanes 2 and 6, and Figure S2), although a de-
crease in the FMRP-CYFIP1 association did occur (see below).
These data indicate that the FMRP-CYFIP1-eIF4E complex is
maintained primarily by protein-protein interactions.
To investigate whether the binding of the CYFIP1-FMRP com-
plex to m7GTP was mediated by FMRP, we performed m7GTP
chromatography with FMR1 KO brain extracts (Figure 1E). The
eIF4E-CYFIP1 association did not require FMRP (Figure 1E,
lane 3). Furthermore, addition of exogenous human 4E-BP1
(Haghighat et al., 1995) to brain extracts decreased the amount
of FMRP-CYFIP1 bound to eIF4E (Figure 1F, lanes 2–4), sug-
gesting that they competed for the same site on eIF4E. This
was confirmed with a 4E-BP mutated in the eIF4E-binding site
(Figure S3). We conclude from these data that the FMRP-CYFIP1
complex binds eIF4E.
Translational repression occurs when 4E-BPs bind eIF4E
to the exclusion of eIF4G (Marcotrigiano et al., 1999; Richter and
Sonenberg, 2005). Consequently, we investigated whether the
absence of a functional eIF4GI impaired the binding of
CYFIP1-FMRP complex to eIF4E. After inactivation of eIF4GI by
cleavage (Gradi et al., 1998) (Figure 1G, lane 1, asterisk), CYFIP1
and FMRP still bound eIF4E (Figure 1G, lane 2), indicating that
binding of CYFIP1 to eIF4E does not require functional eIF4G.
PABP at the 30 terminus of mRNA interacts with the 50 cap-
binding complex and circularizes mRNAs (Mazumder et al.,
2003). Furthermore, the noncoding RNA BC1, which resides in
the FMRP complex (Zalfa et al., 2003, 2005; Gabus et al.,
2004; Johnson et al., 2006; Centonze et al., 2007b) also binds
PABP (West et al., 2002). To test whether the FMRP-CYFIP1
complex simultaneously interacts with PABP, we used poly(A)-
Sepharose beads to isolate PABP and associated factors from
brain extracts. The FMRP-CYFIP1 complex was recovered to-
gether with PABP (Figure S4A). The binding of CYFIP1 to
PABP was independent of FMRP and BC1 RNA, as shown by
the use of FMR1 and BC1 KO (Skryabin et al., 2003) brain ex-
tracts (Figure S4A). Moreover, the recovery of the FMRP-CYFIP1
complex was not due to nonspecific binding of CYFIP1 or FMRP
to the polyribonucleotides affixed to the beads (Figure S4B).
PABP and FMRP were also coimmunoprecipitated (Figure 1C,
lane 4), indicating that FMRP and CYFIP1 are present in a com-
plex containing both eIF4E and PABP.
CYFIP1 Binds Directly and Specifically to eIF4E
Because CYFIP1 bound m7GTP (Figure 1B) independently of
FMRP (Figure 1E), we hypothesized that CYFIP1 might be a novelell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc. 1043
Figure 1. FMRP-CYFIP1 mRNP Interacts with the Translational Initiation Complex
(A) Cosedimentation of proteins on a 5%–25% sucrose gradient. The 80S monosome, the 60S and 40S subunits, and the very light mRNPs were detected by
absorbance of 254 nm light. FMRP, CYFIP1, eIF4E, ribosomal protein S6 (rpS6), PABP, and eIF6/p27 were detected by immunoblotting.
(B) The initiation complex contains CYFIP1. Mouse brain proteins eluted from m7GTP-Sepharose by free m7GTP were analyzed by immunoblotting for CYFIP1,
FMRP, eIF4E, PABP, b-Tubulin, Reticulon 1C, and WAVE. Lane 1, input (1/20); lane 2, unbound proteins (1/20); lane 3, specific elution with free m7GTP; and lane 4,
proteins retained on the beads after m7GTP elution (beads). CYFIP1 and FMRP are absent from the last wash (lane 5) and in the GTP elution (lane 7). Proteins
recovered after specific (lane 6) and nonspecific (lane 7) elution. Lane 8, proteins bound to the beads after nonspecific elution.
(C) CYFIP1 and eIF4E are both present in the FMRP complex in vivo. Western blot of proteins from FMR1 KO and wild-type (WT) mouse brain extracts (Input
[1/10], lanes 1 and 2, respectively) and proteins recovered after immunoprecipitation of the FMRP complex. Lane 4 shows detection of FMRP, eIF4E, CYFIP1,
and PABP. Lane 3 is as above in the FMR1 KO extracts.
(D) CYFIP1-eIF4E and CYFIP1-FMRP interactions resist RNase treatment. Lanes 2 and 6 show western blot of proteins recovered after immunoprecipitation of
the CYFIP1 complex from WT mouse brain extracts. Lanes 1 and 3 show supernatants (1/20) after immunoprecipitation with CYFIP1 antibody and rabbit IgG.
Lanes 5 and 7 show supernatants (1/20) after CYFIP1 and IgG immunoprecipitation in the presence of RNase. Lanes 4 and 8 show immunoprecipitations
with rabbit IgG.
(E) FMRP absence does not interfere with CYFIP1-eIF4E complex formation. The same experiment as in (B) was performed with FMR1 KO mouse brain extract.
Lane 1, input (1/20); lane 2, unbound proteins; lane 3, m7GTP-eluted proteins; and lane 4, proteins recovered from the beads after m7GTP elution (Beads).
(F) Human 4E-BP1 competes with CYFIP1 for eIF4E binding. Lane 1, specifically eluted proteins (same as in [B]). Lanes 2–4, increasing amounts of wild-type
human 4E-BP1 were added to brain extracts before m7GTP chromatography (lanes 2–4). Western blotting was used to detect the levels of bound CYFIP1,
FMRP and eIF4E.
(G) CYFIP1 binds the eIF4E complex independent of eIF4G. Lane 1, input (1/20) of the HeLa cytoplasmic extracts incubated with Polio-2A protease; lane 2,
proteins retained on the column.eIF4E-binding protein. eIF4G and several characterized 4E-BPs
share a short consensus motif that is responsible for binding to
eIF4E (Richter and Sonenberg, 2005). Therefore, we used multi-
sequence alignments to search for a similar peptide that is con-
served in the CYFIP protein family. A candidate peptide (residues
733 to 751, human CYFIP1, Swissprot annotation Q14467) was
identified in the central region of CYFIP1. Here, several amino
acids are conserved among CYFIP and human 4E-BPs, 4G-I,
and 4G-III (Figure 2A). To validate the functional significance of1044 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.this similarity, we compared a structural arrangement of the
CYFIP1 peptide spanning residues 733 to 751 with the known
structure of eIF4E when complexed with the 4E-BP1 peptide
(Tomoo et al., 2005). Indeed, the CYFIP1 peptide (blue ribbon
in Figure 2B) could potentially adopt the peculiar ‘‘reverse
L shaped’’ structure with two a-helical turns located at its center
that are stabilized by two internal salt bridges between residues
Asp742-Arg744 and Glu748-Lys750. Moreover, the CYFIP1
peptide docks onto the molecular binding surface of eIF4E (red
Figure 2. Multiple Alignment ofMammalian,
Zebrafish, and Drosophila CYFIP1 and
Canonical 4E-BPs
(A) The gray and black-boxed amino acids in the
multiple sequence alignment are conserved and
identical residues, respectively, that fold and inter-
act with eIF4E. Black arrows denote internal salt
bridges and one salt bridge with eIF4E.
(B) Hypothetical interactions between eIF4E, rep-
resented as a red molecular surface, and CYFIP1
peptide, shown as a blue spiral ribbon.
(C) Structural prediction of a complex among
4E-BP (red), the m7GTP cap (gray molecule), and
the CYFIP1 peptide (blue). The 4E-BP peptide
(purple) found in the crystal structure almost
perfectly overlaps with the CYFIP1 peptide.
(B) and (C) were produced with the UCSF Chimera
program (Pettersen et al., 2004).ribbon; Figures 2B and 2C), where 12 out of the 16 interactions
formed between eIF4E and 4E-BP1 (Marcotrigiano et al., 1999;
Tomoo et al., 2005) are conserved. In particular, the internal
salt bridge Asp742-Arg744 (Figure 2B and Figure S6A) restricts
the available conformations of the basic residue Lys743 and is
thus locked in a favorable position for the formation of a salt
bridge with Glu132 of eIF4E (Figure 2B). The 4E-BP1 peptide
(purple ribbon, Figure 2C) and the CYFIP1 binding peptide
(blue ribbon, Figure 2C) overlap in their ‘‘reverse L shaped’’ pre-
dicted structure and fit into the eIF4E pocket. The m7GTP-
Sepharose chromatography (Figure 1) and the in silico analysis
(Figure 2) predict that residues 733 to 751 of CYFIP1 may fold
into an eIF4E-binding domain even though the amino acid se-
quence does not conform to the previously established consen-
sus YxxxxLL (Mader et al., 1995; Altmann et al., 1997). The
charged residues implicated in the interaction are important for
establishing the recognition between CYFIP1 and eIF4E. Inter-
estingly, this pattern is common among three different protein
families (CYFIP, 4G, 4E-BPs) that interact with eIF4E (Figure 2A).
To determine whether CYFIP1 is a 4E-BP, we performed
GST-Sepharose pull-down assays using in vitro-synthesized
35S-methionin-labeled proteins. Like 4E-T (Ferraiuolo et al., 2005)
(Figure 3A, lane 7), CYFIP1 was precipitated specifically by
GST-eIF4E (Figure 3A, compare lane 4 with lanes 2 and 3), indi-
cating that eIF4E directly interacts with CYFIP1. The binding of
CYFIP1 to the GST-eIF4E W73A mutant was reduced by 70%,
similar to the effect on 4E-T (Figure 3B). eIF4E simultaneously
interacts with CYFIP1 and m7GTP, because both proteins were
retained on m7GTP-Sepharose beads. The retention of CYFIP1
was insensitive to RNase and DNase (Figure S5). To verify the
importance of the putative eIF4E-binding region for the eIF4E-
CYFIP1 interaction, we introduced several mutations in the
CYFIP1 sequence (Figure 3C), followed by chromatography on
m7GTP-Sepharose (Figure 3D). First, the Asp742 and Arg744
residues were both mutated to alanine, thus removing the salt
bridge at the beginning of the a helix and presumably allowing
more flexibility of the critical Lys743. This mutant (A-A) bound
20% less efficiently than did the wild-type. We introduced other
mutations that affect both internal salt bridges (Asp742Lys;
Arg744Glu; Glu748Lys) and invert the electric charge of the crit-
ical lysine that is predicted to interact with eIF4E (Lys743Glu).Binding of this quadruple mutant (KEE-K) was reduced even fur-
ther (by 60%), indicating that this region of CYFIP1 is involved in
eIF4E binding. Finally, we studied the importance of the lysine
that presumably interacts with eIF4E, mutating it to glutamate
(-E-). This single substitution had an effect similar to that of the
quadruple mutation; a reduction of 70% (compare the last two
bars in Figure 3D, right panel). Because the substitution of
Lys743 with a residue of opposite charge did not induce desta-
bilization of the ‘‘reverse L shaped’’ structure of the CYFIP1 pep-
tide, the strong inhibition of eIF4E binding indicates that Lys743
is involved in the interaction of CYFIP1 with eIF4E, as predicted
by sequence and structural analysis (Figure S6). On the contrary,
the two salt bridges, Asp742-Arg744 and Glu748-Lys750 (Fig-
ure 2A), stabilize the CYFIP1 peptide in a conformation that is
able to interact with the eIF4E protein surface through Lys743.
Mutagenesis of CYFIP1 where a 4E-BP motif similar to the
YxxxxLL consensus was found (WFREFFL) (Figure S7) did not
significantly change the binding to eIF4E.
To assess whether the isolated CYFIP1 peptide, which in-
cludes the eIF4E-binding domain, binds purified eIF4E, we syn-
thesized wild-type (WT) and two mutant peptides (K-EE-K and
-E-, Figure 3C) affixed to biotin. The western blot in Figure 3E
shows that under stringent conditions (300 mM NaCl), no
eIF4E bound to either the control (lane 2) or the CYFIP1 mutant
peptides (lanes 4 and 5), whereas the streptavidin beads con-
taining the WT peptide efficiently bound purified human eIF4E
(lane 3). In less stringent conditions (150 mM NaCl, lower panel)
the mutant peptides also bound some eIF4E but with lower effi-
ciency than did the WT peptide. Therefore, the region of CYFIP1
with structural homology to the 4E-BPs does indeed bind eIF4E.
CYFIP1 specifically and directly interacts with eIF4E through the
noncanonical motif DKRLRSECK, where the lysine at the second
position is critical for the interaction.
The FMRP-CYFIP1 Complex Is Consolidated
by Binding to RNAs
To address the role of CYFIP1 in vivo, we transfected mamma-
lian cells with DNA encoding this protein; as expected, overex-
pression of CYFIP1 repressed general translation. Silencing of
CYFIP1 increased general translation (Figure S8B). TargetingCell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc. 1045
Figure 3. eIF4E and CYFIP1 Interact Directly
(A) GST pull-down assays. E. coli-expressed GST, GST-DCOH, and GST-eIF4E were immobilized on glutathione-Sepharose and incubated with 35S-methionine-
labeled CYFIP1 and 4E-T. Lanes 1 and 5, inputs. GST-eIF4E bound CYFIP1 (compare lanes 2–4) and 4E-T (positive control, lane 7).
(B) GST fusion protein binding assays. GST-eIF4EW73A mutant protein (lanes 2 and 5) or wild-type eIF4E (lanes 3 and 6) was incubated with 35S-methionine-
labeled 4E-T or CYFIP1 proteins. The relative intensities of CYFIP1 or 4E-T (bound proteins:input) were quantified. Proteins bound to GST-eIF4E W73A (dark
gray bars) were compared to proteins bound to GST-eIF4E (100% binding, light-gray bars) (n = 5) ***p < 0.001, Student’s t test.
(C) CYFIP1 amino acid sequence of the WT and mutant eIF4E-binding peptide. A-A, KEE-K, and -E- mutants are shown.
(D) m7GTP binding assays. 35S-methionine-labeled wild-type or mutant CYFIP1 was applied to m7GTP-sepharose beads. Lanes 1, 3, 5, and 7 represent the input
of WT and mutant CYFIP1 proteins, respectively (1/10). Lanes 2, 4, 6, and 8 represent the CYFIP1 proteins bound to m7GTP beads. Relative intensities (bound:
input) of WT and CYFIP1 mutants were quantified as described before (n = 8). ***p < 0.001, **p < 0.01, ANOVA and Dunnett’s multiple comparison tests.
(E) Peptide binding assay. Human GST-eIF4E was applied to streptavidin beads containing wild-type or mutant CYFIP1 biotinylated peptides (sequences in [C])
or unrelated peptide with a biotin added to the N terminus. The bound eIF-4E was detected by immunoblotting. Lane 1, input (1/20); lane 2, unrelated peptide; lane
3, WT peptide; and lanes 4 and 5, K-EE-K and -E- mutant peptides, respectively.of CYFIP1 to a specific mRNA further reduces its expression
(Figures S8A–S8C).
According to our model, FMRP recruits CYFIP1 to mRNAs. To
test this model, we used 35S-labeled FMRP and CYFIP1 proteins
and the FMRP target mRNA encoding Arc/Arg3.1. GST-eIF4E
pull-down experiments showed that eIF4E did not bind signifi-
cantly to FMRP (Figure 4A, compare lane 3 with lane 7), whereas
it binds to CYFIP1, as shown before (compare lane 4 to lane 8).
When capped-Arc mRNA was added, CYFIP1 and especially
FMRP interacted more efficiently with eIF4E (Figure 4A, lane 6).
The specificity was confirmed by the reduced recovery of the
FMRP-CYFIP1 complex in presence of a nonneuronal mRNA
(capped-luciferase mRNA), as shown in Figure 4A (lane 10).
Some residual FMRP and CYFIP1 bound also to luciferase
mRNA, in agreement with the fact that CYFIP1 also inhibits lucif-
erase mRNA (by 25%; Figure S8). Thus, the interaction between
FMRP/CYFIP1 and eIF4E is increased and possibly stabilized by
the presence of target mRNAs, consistent with the decreased
coprecipitation of FMRP with CYFIP1 after RNase treatment
(Figure 1D).
Blocking of BC1 RNA in vitro reduces the affinity of FMRP to at
least some of its target mRNAs (Zalfa et al., 2003). We therefore1046 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.tested whether the absence ofBC1RNA interferes with the bind-
ing of FMRP-CYFIP1 to eIF4E. When m7GTP-Sepharose and
brain extracts from BC1 KO mice were used, there was a signif-
icant decrease (by 60%) in the amount of recovered FMRP
(Figure 4B, lane 7). This effect is consistent with the decreased
coprecipitation of FMRP with CYFIP1 after RNase treatment
(Figure 1D). Furthermore, CYFIP1 formed an RNP containing
BC1 RNA (Figure 4B and Figure S9), and in the absence of
FMRP, the association of BC1 RNA with CYFIP1 decreased
(Figure 4C), indicating that FMRP and BC1 require each other
for optimal interaction with CYFIP1 and eIF4E.
We then assessed whether CYFIP1 is associated with mRNAs
in the brain. Figure 4D (lanes 2 and 3) shows that Map1b mRNA
(Bagni and Greenough, 2005) was detected in the CYFIP1 immu-
noprecipitate. One negative control was neuronal D2DR mRNA,
whose metabolism is not affected by FMRP (Centonze et al.,
2007a). Other FMRP target mRNAs were also investigated. The
association of Map1b, aCaMKII, and Arc (Zalfa et al., 2003),
but possibly not of App (Westmark and Malter, 2007), with the
CYFIP1 complex was decreased in the absence of BC1 RNA
(Figure 4D, Figure S9). RT-Q-PCR was also performed forMap1b
mRNA (Figure 4E), confirming and extending our previous data
Figure 4. RNA Facilitates CYFIP1-FMRP Complex Formation
(A) Arc mRNA facilitates the CYFIP1-FMRP-eIF4E complex formation. Lanes 1 and 2, inputs (1/10) of 35S-methionine-labeled FMRP and CYFIP1; lane 3, FMRP
binding to the GST-eIF4E; lane 4, CYFIP1 binding to GST-eIF4E; lane 5, FMRP + CYFIP1 binding to GST-eIF4E in presence of uncappedArcmRNA; lane 6, FMRP +
CYFIP binding to the GST-eIF4E in the presence of m7G-cappedArcmRNA; lane 7, FMRP binding to GST; lane 8, CYFIP1 binding to GST; lane 9, FMRP + CYFIP1
binding to GST in the presence of firefly m7G-capped luciferasemRNA; and lane 10, FMRP + CYFIP1 binding to GST-eIF4E in the presence of firefly m7G-capped
luciferase mRNA.
(B) BC1 RNA increases eIF4E-CYFIP1-FMRP complex formation. Extracts from WT or BC1 KO brains were incubated with m7GTP-Sepharose and m7GTP-
eluted proteins were separated by SDS-PAGE. CYFIP1, FMRP, and eIF4E were detected by immunoblotting. Lanes 1 and 5, inputs (1/20), lanes 2 and 6, un-
bound proteins (1/20); lanes 3 and 7, specific elution with free m7GTP; and lanes 4 and 8, proteins bound to the beads after specific elution. The level of FMRP
was normalized for the amount of eIF4E in the specific elution (lanes 3 and 7). Average of independent experiments is plotted on the histogram (n = 6, right panel).
**p < 0.01, Student’s t test.
(C) CYFIP1 is part of a neuronal RNP. RT-Q-PCR of BC1 RNA from wild-type (WT) and FMR1 KO brain extracts was performed after CYFIP1 or IgG immuno-
precipitation (n = 4). **p < 0.01, Student’s t test.
(D) After CYFIP1 immunoprecipitation from WT, FMR1, and BC1 KO brain extracts, the RNA was extracted, and RT-PCR was used to detect Map1b and D2DR
mRNAs. Lanes 1, 4, and 7 represent the inputs (1/10). Lanes 2, 5, and 8 contain the immunoprecipitated RNA from WT, FMR1, and BC1 KO extracts, respec-
tively. Lanes 3, 6, and 9 reflect the mRNA associated with the control rabbit IgG. Lower panel: a western blot from the immunoprecipitated CYFIP1 performed
from one-fourth of the same experiment used for the RT-PCR.
(E) RT-Q-PCR of CYFIP1-associated Map1b mRNA. RT-Q-PCR of Map1b from WT, FMR1, and BC1 KO brain extracts was performed after CYFIP1 or control
IgG immunoprecipitation (n = 7). *p < 0.05, ANOVA and Dunnett’s multiple comparison tests.Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc. 1047
Figure 5. The CYFIP1-eIF4E Complex Is Activity-Regulated
(A) CYFIP1-eIF4E colocalization in dendrites under resting and stimulated conditions. Cortical neurons (14 DIV) were stained for CYFIP1 (red) and eIF4E (green)
(colocalization is in yellow) under control conditions (CTR) (subpanels A–D) or after BDNF stimulation (subpanels E–P) at three different times. Subpanels D, H, L,
and P show enlargements of the areas boxed in white with white arrowheads pointing to colocalization of CYFIP1 and eIF4E. Quantification of four independent
experiments (a total of 320 neurites for each condition) was performed with the ImageJ program package and reported as a histogram. ANOVA, post hoc Scheffe`
test; ***p < 0.0001 and ***p < 0.001 at 30 min and 1 hr, respectively, and p = 0.99 at 4 hr. The scale bar represents 10 mm.
(B) CYFIP1-eIF4E-FMRP association in resting and stimulated neuronal cultures. CYFIP1 was immunoprecipitated under control conditions (lane 2, bottom panel)
or after BDNF treatment (lane 6), and its presence with eIF4E and FMRP was analyzed by western blotting. Under control conditions, eIF4G was absent from the
complex (lane 2). Quantification of eight independent experiments to detect eIF4E and four to detect FMRP is reported in the histogram. The amount of coim-
munoprecipitated eIF4E or FMRP was normalized for the immunoprecipitated CYFIP1. *p < 0.05, one-sample Student’s t test.that a significant (60%) decrease in the association of this tran-
script with CYFIP1 occurred in BC1 KO mice. Another putative
FMRP target is Fmr1 mRNA (Schaeffer et al., 2001; Miyashiro
et al., 2003), which we did not detect in the neuronal CYFIP1
complex (Figure S9). Taken together, these data show that
CYFIP1 requires BC1 RNA and FMRP for optimal association
with—and translational repression of—some key brain mRNAs.
The FMRP-CYFIP1 Complex Is Activity-Regulated
in Neurons
Next, we analyzed the distribution of FMRP-CYFIP1, FMRP-
eIF4E, and CYFIP1-eIF4E in primary cultures of hippocampal
neurons. eIF4E was colocalized with CYFIP1 and FMRP in cell
bodies and dendrites (Figure S10; see Figure S11 for specificity
of antibody reaction). In some cases, synaptic activity and/or de-
velopmental transitions can alleviate translational repression
(Gebauer and Hentze, 2004; Richter and Sonenberg, 2005); con-1048 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.sequently, we investigated whether BDNF stimulation caused re-
lease of eIF4E from the FMRP-CYFIP1 complex. Resting neuro-
nal cultures are shown in Figure 5A, subpanels A–D. BDNF was
added to hippocampal neurons for 30 min, 1 hr, or 4 hr, followed
by eIF4E and CYFIP1 immunodetection (Figure 5A, subpanels
E–P). The overlap of CYFIP1 and eIF4E signals changed signifi-
cantly with BDNF treatment; it decreased by 30% after 1 hr of
treatment. Over 4 hr, however, the difference from baseline
was not significant (Figure 5A, subpanels M–P). To verify that
the diminished colocalization corresponded to a decrease in
the CYFIP1-eIF4E complex, we performed CYFIP1 immunopre-
cipitations with similarly treated neurons (Figure 5B). As ex-
pected, the yield of coprecipitating eIF4E, normalized for the
amount of precipitated CYFIP1, was reduced (by 40%) after
30 min of BDNF treatment, although FMRP levels did not change
(Figure 5B). These data suggest that diminished colocalization
reflects a decrease in complex formation. Moreover, eIF4G did
not coprecipitate with CYFIP1 (Figure 5B, bottom panel), further
indicating that CYFIP1, like other 4E-BPs, competes with eIF4G
for binding to eIF4E. These observations indicate that the inhib-
itory FMRP-CYFIP1-eIF4E complex is dynamically regulated in
an activity-dependent manner to repress and then possibly re-
lease dendritic mRNAs for translation.
The FMRP-CYFIP1-eIF4E Complex Is Present
and Active at Synapses
To address the functional significance of the FMRP-CYFIP1-
eIF4E complex at synapses, we prepared synaptoneurosomes
(Pilo Boyl et al., 2007), the enrichment of which was monitored
by PSD-95 levels in the synaptic fraction compared to total ex-
tracts (Figure S12). m7GTP-Sepharose beads were then in-
cubated with extracts from cortical synaptoneurosomes.
Figure 6A shows that CYFIP1 bound to the beads was specifi-
cally eluted with m7GTP, and FMRP was also detected in this
complex (Figure 6A, lane 3).
We then stimulated cortical synaptoneurosomes with BDNF,
immunoprecipitated CYFIP1, and examined coprecipitated
eIF4E or associated mRNAs. In control experiments, eIF4E
was associated with CYFIP1 (Figure 6B, lane 2). After 30 min of
BDNF stimulation, a fraction of the eIF4E was released from
the CYFIP1 complex (Figure 6B, lane 5 and right panel). The
disassembly of the CYFIP1-eIF4E complex suggests that target
mRNA translation was activated; indeed, around 80% of Map1b
and BC1 RNAs, as measured by RT-Q-PCR, was released from
the CYFIP1 complex after stimulation (Figure 6C).
Because FMRP responds to mGluR stimulation (Weiler et al.,
1997; Huber et al., 2002; Dolen et al., 2007), we treated hippo-
campal and cortical synaptoneurosomes with the group I mGluR
agonist DHPG. After 5 min of stimulation, a significant decrease
of eIF4E in the CYFIP1 complex was observed (Figure 6D). Lon-
ger stimulations (DHPG for 15 min) caused a significant increase
in CYFIP1-eIF4E complex formation (Figure S13), suggesting that
mGluR stimulation induced an initial release of CYFIP1-eIF4E-
regulated translation followed by rapid overcompensation. We
also electroporated primary cortical neurons with siRNAs di-
rected againstCYFIP1; reduction of CYFIP1 protein lead to an in-
crease of MAP1B (Figure S14). Finally, extracts from CYFIP1 het-
erozygote mice (CYFIP1+/) were analyzed; in this case, MAP1B
protein increased by 25% compared to the WT. Furthermore,
the translation of aCaMKII and APP proteins was also upregu-
lated by 70% and 90%, respectively (Figure 6E, compare
lanes 1 and 2). Taken together, these data show that CYFIP1 reg-
ulates the expression of Map1b and other FMRP target mRNAs.
DISCUSSION
Although CYFIP1 was identified as an FMRP-interacting factor
as well as a component of the WAVE complex involved in actin
polymerization, its molecular function was unknown (Schenck
et al., 2001; Kunda et al., 2003). We show that CYFIP1 binds
eIF4E in brain extracts, synaptoneurosomes (Figures 1 and 6),
and in vitro (Figure 3A). CYFIP1 contains a peptide that is pre-
dicted to exhibit structural similarity to the canonical eIF4E-bind-
ing domain (Richter and Sonenberg, 2005) (Figure 2A). Indeed,
the integrity of this sequence motif is required for efficienteIF4E binding (Figures 3C–3E). CYFIP1 is not the first eIF4E-
binding protein that does not contain a well-conserved eIF4E-
binding peptide; the Xenopus oocyte maturation factor Maskin
(Richter and Sonenberg, 2005) is another example. It seems
therefore likely that by convergent evolution, several protein
families developed a surface domain that can efficiently block
access of eIF4G to eIF4E.
FMRP Recruitment of CYFIP1 Represses Translation
The 4E-BPs bind eIF4E independently of other factors and thus
downregulate the translation of many mRNAs that have no obvi-
ous sequence similarity (Richter and Sonenberg, 2005). In other
cases, eIF4E-binding proteins are recruited by specific proteins
present only on a subset of mRNAs. For example, Maskin re-
quires the RNA binding protein CPEB (Richter and Sonenberg,
2005), and Cup requires Bruno (Nakamura et al., 2004) or other
proteins (Nelson et al., 2004), depending on the developmental
stage. Here, we show that CYFIP1 inhibits the translation of as-
sociated mRNAs through FMRP (Figure 4). We propose that in
the brain, FMRP helps recruit and/or stabilize CYFIP1 on the 50
end of specific mRNAs to repress translation. Several observa-
tions support this point: the two proteins form a heterodimer
(Schenck et al., 2001); FMRP increases the affinity of CYFIP1
for capped mRNAs (Figure 4A); BC1, an RNA involved in
FMRP-mRNA complex formation (Zalfa et al., 2003, 2005; Ga-
bus et al., 2004), also increases the FMRP-CYFIP1-eIF4E inter-
action (Figure 4B); CYFIP1 is associated with BC1 RNA, Map1b,
aCaMKII, Arc, and App mRNAs in the brain; in FMR1 or BC1 KO
mice, the interaction of these mRNAs with CYFIP1 is decreased
(Figures 4C–4E, Figure S9, and data not shown). Finally, reduc-
tion of CYFIP1 in the brain leads to an increase of MAP1B, APP,
and aCaMKII (Figure 6E). These increases are consistent with
those observed in the absence of FMRP in the mammalian brain
(Zhang et al., 2001; Zalfa et al., 2003; Lu et al., 2004; Hou et al.,
2006; Westmark and Malter, 2007). Fmr1 mRNA, an FMRP tar-
get (Schaeffer et al., 2001; Miyashiro et al., 2003), is not part
of the CYFIP1 mRNP, and consequently FMRP expression
does not change upon CYFIP1 reduction (Figure 6E and Figures
S9 and S14). Perhaps Fmr1 mRNA is regulated by a different
FMRP complex or is not controlled at the translational level.
The FMRP-CYFIP1-eIF4E Complex Responds
to Synaptic Stimulation
One major issue concerning translation in neurons is regulation
by synaptic stimulation. Protein synthesis is activated by several
synaptic stimuli such as BDNF and DHPG. BDNF stimulates
translation via mTOR and ERK-MAPK at synapses and likely in-
volves modulation of initiation. Moreover, BDNF activates the
translation of Arc and aCaMKII mRNAs in dendrites and at syn-
apses (Aakalu et al., 2001; Yin et al., 2002; Schratt et al., 2004).
After application of BDNF to cultured primary neurons and
synaptoneurosomes, we observed a dissociation of eIF4E and
CYFIP1, which coincided with the release of associated
(m)RNAs (Figures 5, 6B, and 6C). In our model (Figure 7), this dis-
assembly would free eIF4E to initiate translation.
DHPG stimulation of mGluR activity also induces translation
initiation via ERK and subsequent eIF4E phosphorylation (Richter
and Klann, 2007). DHPG stimulation of synaptoneurosomesCell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc. 1049
Figure 6. The FMRP-CYFIP1-eIF4E Complex Is Activity Regulated at Synapses
(A) CYFIP1-eIF4E complex is detected in synaptoneurosomes. m7GTP-Sepharose beads were incubated with synaptic extracts; the recovered proteins were
immunoblotted for CYFIP1, FMRP, and eIF4E. Lane 1, input (1/20); lane 2, unbound proteins; lane 3, specific elution with free m7GTP; and lane 4, proteins bound
to the beads after specific elution (beads).
(B) The CYFIP1-eIF4E complex is activity regulated at synapses. Proteins coimmunoprecipitating with CYFIP1 (lanes 2 and 5), respective supernatants (lanes 3
and 6), and inputs (1/40, lanes 1 and 4) were analyzed by immunoblotting. Quantification of four independent experiments is represented in the histogram.
*p < 0.05, one-sample Student’s t test.
(C) CYFIP1 is part of a synaptic BDNF-sensitive mRNP complex. Shown is the amount of Map1b mRNA and BC1 RNA, as determined by RT-Q-PCR, that
coprecipitates with CYFIP1 after mock or BDNF stimulation of synaptoneurosomes (n = 4). Values were normalized for the mock control of each experiment.
***p < 0.001, **p < 0.01, one-sample Student’s t test.
(D) eIF4E is released from the CYFIP1 complex after DHPG stimulation. The experiments were performed as in (B) with DHPG stimulation for 5 min. n = 5,
**p < 0.01, one-sample Student’s t test.
(E) CYFIP1 affects protein levels encoded by some FMRP target mRNAs. Brain proteins from WT (lane 1) or CYFIP1+/ mice (lane 2) were analyzed by immuno-
blotting to detect CYFIP1, FMRP, MAP1B, APP, aCaMKII, LDH, and vinculin levels (left panel). Quantified proteins were normalized for LDH. This ratio in WT mice
was set at 100%. Histogram in the right panel shows the quantification of five independent experiments. **p < 0.01, *p < 0.05, Student’s t test.caused CYFIP1-eIF4E dissociation (Figure 6D), confirming a re-
sponse of FMRP translational repression to mGluR signaling
(Huber et al., 2002; Hou et al., 2006; Dolen et al., 2007). Interest-1050 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.ingly, we detected the release of CYFIP1 from eIF4E only after
a short stimulation (Figure 6D), which could be due to a short
pulse of FMRP dephosphorylation observed under similar
conditions (Narayanan et al., 2007). Alternatively, because Rac1
in its GTP form disassembles the FMRP-CYFIP1 complex inDro-
sophila (Schenck et al., 2003), it is tempting to speculate that
a similar mechanism could also mediate eIF4E dissociation
from CYFIP1.
Relevance for the Fragile X Syndrome
We propose that in the absence of FMRP, which causes FXS,
there would be decreased binding of CYFIP1 to FMRP target
mRNAs. This would relieve translational suppression and induce
higher than normal levels of proteins whose synthesis is under
the control of FMRP. On the other hand, the fact that CYFIP1 as-
sociates with the WAVE complex, which plays a role in actin po-
lymerization (Bogdan et al., 2004), implicates the FMRP regula-
tory complex in synapse maturation. In support of this notion,
synaptic abnormalities observed in mutants affecting Rac1 sig-
naling pathways resemble those in the FXS (Tashiro and Yuste,
2004). Furthermore, the role of CYFIP1 as coregulator of FMRP
may also help to explain the autistic features of FXS because
CYFIP1 has been recently implicated in autism (Nishimura
et al., 2007; Nowicki et al., 2007). Further work is needed to un-
derstand the functional consequences of impaired local protein
synthesis in the developing brain and how this correlates to the
autistic and FXS phenotypes.
EXPERIMENTAL PROCEDURES
Animals
All animals were treated according to institutional and international guidelines
(see the Supplemental Data). The C57/BL6 FMR1 KO mice were provided by
Ben Oostra (Bakker et al., 1994), the 129Sv BC1 KO mice by Juergen Brosius
(Skryabin et al., 2003), and the CYFIP1+/ mice by Walter Witke (M.M. and
W.W., unpublished data). All of the animals used in this study were 3 weeks
old.
Figure 7. Proposed Model for mRNA Translational Repression and
Activation by the CYFIP1-FMRP Complex
The CYFIP1-FMRP or CYFIP1-FMRP-BC1 mRNA complex is transported in
dendrites as translationally silent mRNPs. Some of these mRNPs are also
present at synapses. After synaptic stimulation, and possibly after CYFIP1
and/or FMRP protein modifications, the CYFIP1-FMRP complex is released
from eIF4E, and local mRNA translation ensues.CGST Pull-Down Assay
Plasmids encoding GST, GST-DCOH, GST-eIF4E, and GST-eIF4E Trp73Ala
(see the Supplemental Data) were expressed in E. coli BL21; lysates were clar-
ified and mixed with glutathione-Sepharose 4B beads (Amersham-Biosci-
ences) for 1 hr at 4C. The beads were collected and washed in PBS 13.
Glutathione beads containing the same amount of fusion proteins (5–10 mg)
were incubated in binding buffer (20 mM Tris-HCl [pH 8.0], 100 or 200 mM
NaCl, 1 mM ethylenediaminetetraacetic acid [EDTA], and 0.5% NP-40). Pro-
teins bound to the beads were resolved by SDS-PAGE. The same amounts
of protein were subsequently incubated in 250 ml of binding buffer in the pres-
ence of 5 ml of lysate containing in vitro-synthesized protein (TNT System
Promega). After 90 min incubation at 4C, the beads were washed in binding
buffer and resolved by SDS-PAGE and phosphorimaged.
Protein Extract Preparation
Total mouse brain and cultured primary neurons were homogenized in lysis
buffer (100 mM NaCl, 10 mM MgCl2, 10 mM Tris-HCl [pH 7.5], 1 mM dithio-
threitol, 30 U/ml RNasin, 1% Triton X-100, 0.5 mM Na-orthovanadate,
10 mM b-glycerophosphate, and 10 mg/ml Sigma protease inhibitor), incu-
bated 5 min on ice, and centrifuged at 12,000 g for 8 min at 4C, and the
supernatant was used for immunoprecipitations and m7GTP-Sepharose chro-
matography. For total protein analysis, brains were homogenized in Laemli
buffer, boiled, and vortexed. The procedures were repeated five times.
Immunoprecipitation
Brain (500–800 mg) or cell (200 mg) extracts were used for immunoprecipitation
experiments. For immunoprecipitation of FMRP, brains were prepared as de-
scribed above, and a reversible immunoprecipitation system (Catch and Re-
lease v2.0, Upstate) was used. For CYFIP1, the lysis buffer contained
150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1.5% Triton X-100, and protease in-
hibitors (Sigma). The lysates were centrifuged first at 1000 rpm and then at
10,000 rpm, each for 10 min at 4C. The extracts were incubated with 4 mg
of CYFIP1 polyclonal antibody (see Table S1 for antibodies) overnight at
4C. Twenty microliters of protein A Sepharose (Amersham) previously satu-
rated with 1% BSA in PBS was incubated with the extract for 90 min at 4C.
The beads were washed three times in 1 ml of buffer (150 mM NaCl, 50 mM
Tris-HCl [pH 8.0], and 1% Triton X-100). The same amount of rabbit IgG was
used as control. Immunoprecipitation experiments with CYFIP1 antibody
followed BDNF (30 ng/ml) stimulation of cortical neurons for 30 min before
collecting the cells.
Cosedimentation of Proteins on Polysome-mRNPs Gradients
Total mouse brain was homogenized in lysis buffer (see Protein Extract
Preparation). The supernatants were centrifuged through 5%–25% sucrose
gradients as described in the Supplemental Data. Fractions were analyzed
by immunoblotting.
m7GTP Chromatography
m7GTP-Sepharose beads (Amersham Biosciences) were equilibrated with
buffer A (100 or 200 mM KCl, 50 mM Tris-HCl [pH 7.5], 5–10 mM MgCl2, and
0.5% Triton X-100) plus BSA (0.1 mg/ml) at 4C for 30 min. The resin was
washed and incubated with 500–900 mg of protein extract from mouse brain
for 60 min at 4C; GTP (100 mM) was added to reduce nonspecific binding.
The beads were washed with 0.4 ml of buffer A and then incubated for
30 min with 200 mM of m7GTP. In some cases, 100 mg of RNase A (Sigma)
and 1000 U of RNase T1 (Roche) per mg of protein were added (Nakamura
et al., 2004).
Assay with Biotinylated Peptides
Biotinylated CYFIP1 wild-type ([Btn]AGSLLLDKRLRSECKNQ), mutant
([Btn]AGSLLLKEELRSKCKNQ; [Btn]AGSLLLDERLRSECKNQ), and control
([Btn]GSAPTRPPPLPP) peptides (Sigma) were dissolved in Tris-buffered sa-
line (TBS)/Tween (0.02%); each peptide (25 mg) was incubated with streptavi-
din-conjugated magnetic beads (30 ml, Invitrogen) for 15 min at room temper-
ature in buffer (150 or 300 mM NaCl, 50 mM Tris-HCl [pH 7.5], and 0.1% Triton
X-100). The beads were then washed twice in the same buffer and mixed withell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc. 1051
purified human GST-eIF4E (200 or 400 ng) for 1 hr at 4C. The beads were then
washed, and the protein was eluted, immunoblotted, and probed for eIF4E.
Immunoprecipitation Followed by RT-PCR and RT-Q-PCR Analysis
For RT-PCR and RT-Q-PCR analysis of immunoprecipitates, the beads were
saturated in 1% BSA in PBS and heparin (1 mg/ml). CYFIP1 antibody was
incubated with the beads (90 min at 4C), washed three times (150 mM NaCl,
50 mM Tris-HCl [pH 8.0], and 1% Triton X-100), and incubated with 300 mg
of brain extract or 200 mg of synaptic brain extract plus heparin (0.1 mg/ml)
for 1 hr at 4C. They were then washed, and RNA was eluted in 0.2 M NaAce-
tate, 1 mM EDTA, and 0.2% SDS for 5 min at 95C. RNA was extracted (Trizol,
Invitrogen) and used for p(dN)6-primed RT and PCR with mRNA-specific
primers (Table S2). Real-time PCR was performed with an ABI 7900 Sequence
Detector with dual-labeled TaqMan probes (Applied Biosystems). See the
Supplemental Data for further details.
Neuronal Culture, Stimulation, and Image Analysis
Primary mouse cortical neurons (E15) were prepared as described (Ferrari
et al., 2007); 14 DIV cells were treated with brain-derived neurotrophic factor
(BDNF) (30 ng/ml, Alomone Laboratory) for 30, 60, or 240 min as described
(Takei et al., 2001). They were then fixed with paraformaldehyde (1%–4%),
permeabilized with Triton X-100 (0.2%), and analyzed for CYFIP1 and eIF4E.
See Table S1 for details of the antibodies. The images were acquired with
a confocal laser scanning microscope (LSM510, Zeiss and BIORAD Radiance
2010) with plan neofluar 403 or 633 oil objectives. Quantitative analysis in
double-labeled material was performed blind from four different stimulated
cultures by counting of 80 cells and 20 neurons (for each condition). A total
of 320 dendrites over a length of 50 mm starting 20 mm from the nucleus was
analyzed. Quantification was performed with ImageJ program (1.37v version)
(from ImageJ for microscopy: http://www.macbiophotonics.ca/imagej/
colour_analysis.htm#coloc_ica). See the Supplemental Data for further details.
Synaptoneurosomes
Synaptoneurosomes were prepared by homogenization of fresh cortex tissue
in ice-cold buffer as described (Pilo Boyl et al., 2007). They were resuspended
in HEPES-Krebs buffer (10 mM HEPES [pH 7.4], 150 mM NaCl, 3 mM KCl,
10 mM glucose, 2 mM MgSO4, and 2 mM CaCl2), equilibrated at 37
C for
5 min, and incubated at 37C for 30 min with 200 ng/ml BDNF or for 5 min
and 15 min with 100 mM DHPG. Stimulated and control (buffer treated) synap-
toneurosomes were then lysed as previously described.
Homology Modeling Methods
A multialignment was carried out between a human 4E-BP1 fragment and
twelve sequences of CYFIP 1 and 2, chosen among different species and iso-
forms (data not shown). In this multialignment, only the CYFIP sequences with
a length comparable to that of human CYFIP1 were considered (KIAA0068, ac-
cession number D38549). A region showing a high conservation of residues
that can be considered for the binding with eIF4E was found and modeled
with the 4E-BP1 fragment present depicted by X-ray crystallography used
as a template (Tomoo et al., 2005). The sequence numbering of CYFIP1 resi-
dues used throughout the analysis was made relative to the sequence of
human CYFIP1 (accession number Q14467). See the Supplemental Data for
further details.
Statistical Analysis
Differences between groups were determined by ANOVA and then Sheffe´ mul-
tiple comparison post hoc test, Dunnett’s test, or one-sample Student’s t test,
where appropriate. Student’s t test was used for comparisons where only two
groupswere analyzed. Correlations were determined with Pearson’s correlation
analysis. Significance was accepted at p < 0.05. Error bars represent the SEM.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, 14 fig-
ures, and two tables and can be found with this article online at http://www.
cell.com/cgi/content/full/134/6/1042/DC1/.1052 Cell 134, 1042–1054, September 19, 2008 ª2008 Elsevier Inc.ACKNOWLEDGMENTS
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